DND Share Price

Open 15.64 Change Price %
High 15.74 1 Day -0.64 -4.12
Low 14.75 1 Week 0.00 0.00
Close 14.89 1 Month 0.00 0.00
Volume 119303 1 Year 0.00 0.00
52 Week High 1.68
52 Week Low 0.65
DND Important Levels
Resistance 2 15.81
Resistance 1 15.43
Pivot 15.13
Support 1 14.35
Support 2 13.97
TSE Canada Most Active Stocks
BIN 41.40 -1.62%
BIN 41.40 -1.62%
LSG 2.08 8.33%
LSG 2.08 8.33%
LSG 2.08 8.33%
TBE 0.03 0.00%
MFC 24.30 2.57%
MFC 24.30 2.57%
MFC 24.30 2.57%
MFC 24.30 2.57%
More..
TSE Canada Top Gainers Stocks
TVI 0.02 100.00%
ST 0.02 100.00%
ST 0.02 100.00%
CUR 0.02 100.00%
CUR 0.02 100.00%
CUR 0.02 100.00%
TPL 0.02 100.00%
TPL 0.02 100.00%
QEC 0.74 42.31%
QEC 0.74 42.31%
More..
TSE Canada Top Losers Stocks
GBV 0.46 -24.59%
HE 0.04 -20.00%
HE 0.04 -20.00%
HBP 1.35 -12.90%
HBP 1.35 -12.90%
NKO 0.08 -11.11%
NKO 0.08 -11.11%
NKO 0.08 -11.11%
CCM 0.08 -11.11%
CCM 0.08 -11.11%
More..

Cipher Pharmaceuticals Inc (TSE: DND)

DND Technical Analysis 4
As on 24th Nov 2014 DND Share Price closed @ 14.89 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 9.31 & Buy for SHORT-TERM with Stoploss of 12.74 we also expect STOCK to react on Following IMPORTANT LEVELS.
DND Target for December
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
DND Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Drugs - Generic
Offical website http://www.cipherpharma.com
DND Address
DND
5650 Tomken Road
Unit 16
Mississauga, ON L4W 4P1
Canada
Phone: 905-602-5840
Fax: 905-602-0628
Interactive Technical Analysis Chart Cipher Pharmaceuticals Inc ( DND TSE Canada )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Cipher Pharmaceuticals Inc
DND Business Profile
Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company that commercializes novel formulations of marketed molecules. The company focuses on in-licensing differentiated products, advancing them through the clinical development and regulatory approval stages, and either out-licensing to marketing partners or, in the case of the Canadian market, the company may market the product. Its products include a fenofibrate formulation marketed in the United States as Lipofen; an extended-release tramadol, which is marketed in the United States as ConZip and in Canada as Durela; and a novel formulation of the acne treatment isotretinoin, which is marketed in the United States as Absorica and in Canada as Epuris. The company also has the exclusive Canadian rights to market the Betesil Patch, a medicated plaster for the treatment of inflammatory skin conditions, such as plaque psoriasis. It has a collaborative partnership with Galephar Pharmaceutical Research, Inc. Cipher Pharmaceuticals Inc. was founded in 2000 and is based in Mississauga, Canada.